Genotyping of allelic variants of Plasmodium falciparum merozoite surface proteins 1 and 2 (msp-1 and msp-2), and the glutamate-rich protein is the gold standard for distinguishing reinfections from recrudescences in antimalarial drug trials. We compared performance of the recently developed 24-single-nucleotide polymorphism (SNP) Barcoding Assay against msp-1 and msp-2 genotyping in a cluster-randomized effectiveness trial of artemether- lumefantrine and dihydroartemisinin-piperaquine in Malawi. Rates of recrudescence and reinfection estimated by the two methods did not differ significantly (Fisher's exact test; P = 0.887 and P = 0.768, respectively). There was a strong agreement between the two methods in predicting treatment outcomes and resolving the genetic complexity of malaria infections in this setting. These results support the use of this SNP assay as an alternative method for correcting antimalarial efficacy/effectiveness data.
Fulakeza, J. R. M., Banda, R. L., Lipenga, T. R., Terlouw, D. J., Nkhoma, S. C., & Hodel, E. M. (2018). Comparison of two genotyping methods for distinguishing recrudescence from reinfection in antimalarial drug efficacy/effectiveness trials. American Journal of Tropical Medicine and Hygiene, 99(1), 84–86. https://doi.org/10.4269/ajtmh.18-0002